Abstract
BackgroundBlockade of receptor activator of nuclear factor kappa B ligand (RANKL), using denosumab retards bone damage in RA. Whether RANKL blockade allows repair of existing bone erosions is so far...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
